$BNTC
Benitec Biopharma Inc.

2024 Q4 Form 10-Q Financial Statement

#000119312524258672 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $2.206M
YoY Change 42.23%
% of Gross Profit
Research & Development $3.585M
YoY Change -19.06%
% of Gross Profit
Depreciation & Amortization $25.00K
YoY Change 31.58%
% of Gross Profit
Operating Expenses $5.791M
YoY Change -1.41%
Operating Profit -$5.791M
YoY Change -1.41%
Interest Expense $604.0K
YoY Change -10166.67%
% of Operating Profit
Other Income/Expense, Net $732.0K
YoY Change -1015.0%
Pretax Income -$5.059M
YoY Change -15.03%
Income Tax
% Of Pretax Income
Net Earnings -$5.100M
YoY Change -15.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.48
COMMON SHARES
Basic Shares Outstanding 23.22M 10.56M
Diluted Shares Outstanding 10.64M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.84M
YoY Change 162.3%
Cash & Equivalents $67.80M
Short-Term Investments
Other Short-Term Assets $426.0K
YoY Change -11.62%
Inventory
Prepaid Expenses $481.0K
Receivables $4.000K
Other Receivables $0.00
Total Short-Term Assets $68.34M
YoY Change 158.73%
LONG-TERM ASSETS
Property, Plant & Equipment $154.0K
YoY Change 126.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $56.00K
YoY Change -34.12%
Total Long-Term Assets $439.0K
YoY Change -31.51%
TOTAL ASSETS
Total Short-Term Assets $68.34M
Total Long-Term Assets $439.0K
Total Assets $68.77M
YoY Change 154.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $903.0K
YoY Change -40.9%
Accrued Expenses $3.591M
YoY Change 21.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.553M
YoY Change 0.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $41.00K
YoY Change -80.57%
Total Long-Term Liabilities $41.00K
YoY Change -80.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.553M
Total Long-Term Liabilities $41.00K
Total Liabilities $4.594M
YoY Change -3.18%
SHAREHOLDERS EQUITY
Retained Earnings -$195.3M
YoY Change 12.35%
Common Stock $260.5M
YoY Change 32.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.18M
YoY Change
Total Liabilities & Shareholders Equity $68.77M
YoY Change 154.22%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.100M
YoY Change -15.0%
Depreciation, Depletion And Amortization $25.00K
YoY Change 31.58%
Cash From Operating Activities -$4.600M
YoY Change 0.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.66M
YoY Change -22.44%
NET CHANGE
Cash From Operating Activities -4.600M
Cash From Investing Activities 0.000
Cash From Financing Activities 21.66M
Net Change In Cash 16.98M
YoY Change -27.41%
FREE CASH FLOW
Cash From Operating Activities -$4.600M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4620206
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001808898
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
001-39267
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
BENITEC BIOPHARMA INC.
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
3940 Trust Way
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
CY2024Q3 dei City Area Code
CityAreaCode
510
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
780-0819
CY2024Q3 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
CY2024Q3 dei Trading Symbol
TradingSymbol
BNTC
CY2024Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23216425
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67841000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50866000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
64000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
4000
CY2024Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
229000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
426000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
516000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
68335000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
51674000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
154000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
179000
CY2024Q3 us-gaap Deposit Assets
DepositAssets
25000
CY2024Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
56000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
62000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
204000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
270000
CY2024Q3 us-gaap Assets
Assets
68774000
CY2024Q2 us-gaap Assets
Assets
52210000
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3847000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4165000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
495000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
475000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
211000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
284000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4553000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4924000
CY2024Q3 bntc Non Accrued Accrued Employee Benefits Non Current
NonAccruedAccruedEmployeeBenefitsNonCurrent
41000
CY2024Q2 bntc Non Accrued Accrued Employee Benefits Non Current
NonAccruedAccruedEmployeeBenefitsNonCurrent
38000
CY2024Q3 us-gaap Liabilities
Liabilities
4594000
CY2024Q2 us-gaap Liabilities
Liabilities
4962000
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17893765
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17893765
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10086119
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10086119
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
260490000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238398000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195318000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190259000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-993000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-892000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
64180000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
47248000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68774000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52210000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q3 us-gaap Revenues
Revenues
0
CY2023Q3 us-gaap Revenues
Revenues
0
CY2024Q3 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
0
CY2023Q3 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
-106000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3585000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4429000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2206000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1551000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
5791000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5874000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5791000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5874000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
93000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-56000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
604000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
732000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-80000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5954000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-101000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
50000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-101000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
50000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5160000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5904000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5954000
CY2024Q3 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
0
CY2023Q3 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
619000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5059000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6573000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.05
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10644533
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10644533
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2157065
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2157065
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2023Q3 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
27919000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
50000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5954000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
22308000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
47248000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1655000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20002000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
435000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-101000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
64180000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5954000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000
CY2024Q3 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
66000
CY2023Q3 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
63000
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
435000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
91000
CY2024Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-226000
CY2023Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
0
CY2024Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-100000
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-709000
CY2024Q3 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
-322000
CY2023Q3 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
566000
CY2024Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
16000
CY2023Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4000
CY2024Q3 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-73000
CY2023Q3 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-67000
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4586000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4577000
CY2024Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q3 bntc Proceeds From Exercise Of Pre Funded Warrants And Common Warrants
ProceedsFromExerciseOfPreFundedWarrantsAndCommonWarrants
21655000
CY2023Q3 bntc Proceeds From Exercise Of Pre Funded Warrants And Common Warrants
ProceedsFromExerciseOfPreFundedWarrantsAndCommonWarrants
30883000
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2964000
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21655000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27919000
CY2024Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-93000
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16976000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23387000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50929000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67905000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25877000
CY2024Q3 bntc Warrant Antidilution Provision
WarrantAntidilutionProvision
0
CY2023Q3 bntc Warrant Antidilution Provision
WarrantAntidilutionProvision
619000
CY2024Q3 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-11-22
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use of Estimates </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements relate to accrued research and development expense and valuation of equity-based instruments issued for other than cash. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </div>
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
64000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concentrations of Risk </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash . The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div>
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27645640
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35453286
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5100000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6000000
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4600000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4600000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67800000
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5749152
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.8
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2584239
CY2024Q2 bntc Class Of Warrant Purchase Price Per Warrant
ClassOfWarrantPurchasePricePerWarrant
4.7999
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q2 bntc Gross Proceeds From Issuance Of Warrants
GrossProceedsFromIssuanceOfWarrants
40000000
CY2024Q3 us-gaap Cash
Cash
21700000
CY2024Q3 us-gaap Due From Banks
DueFromBanks
67841000
CY2024Q2 us-gaap Due From Banks
DueFromBanks
50866000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
64000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
67905000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50929000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
481000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
577000
CY2024Q3 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2024Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2024Q3 us-gaap Other Assets
OtherAssets
482000
CY2024Q2 us-gaap Other Assets
OtherAssets
578000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
62000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
426000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
516000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1583000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1583000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1429000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1404000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
154000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
179000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
903000
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1351000
CY2024Q3 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
101000
CY2024Q2 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
75000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
97000
CY2024Q3 bntc Accrued Clinical Development Project Costs
AccruedClinicalDevelopmentProjectCosts
2646000
CY2024Q2 bntc Accrued Clinical Development Project Costs
AccruedClinicalDevelopmentProjectCosts
2504000
CY2024Q3 bntc Accrued Patent Expenses
AccruedPatentExpenses
7000
CY2024Q2 bntc Accrued Patent Expenses
AccruedPatentExpenses
0
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
138000
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3847000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4165000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
270000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
66000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
204000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
284000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
73000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
211000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
211000
CY2024Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y8M12D
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0467
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
215000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
215000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
211000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.22
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.9299
CY2023Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
27900000
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5749152
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.8
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26463500
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
34271146
CY2024Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
1.85
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26463500
CY2024Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
1.57
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
435000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3800000
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001193125-24-258672-index-headers.html Edgar Link pending
0001193125-24-258672-index.html Edgar Link pending
0001193125-24-258672.txt Edgar Link pending
0001193125-24-258672-xbrl.zip Edgar Link pending
bntc-20240930.xsd Edgar Link pending
d889203d10q.htm Edgar Link pending
d889203dex311.htm Edgar Link pending
d889203dex312.htm Edgar Link pending
d889203dex321.htm Edgar Link pending
d889203dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g889203dsp37.jpg Edgar Link pending
g889203dsp40.jpg Edgar Link pending
g889203dsp40a.jpg Edgar Link pending
g889203dsp41.jpg Edgar Link pending
g889203dsp42.jpg Edgar Link pending
g889203dsp42a.jpg Edgar Link pending
g889203dsp43.jpg Edgar Link pending
g889203dsp44.jpg Edgar Link pending
g889203dsp45.jpg Edgar Link pending
g889203dsp46.jpg Edgar Link pending
g889203dsp47.jpg Edgar Link pending
g889203dsp48.jpg Edgar Link pending
g889203g0501074535811.jpg Edgar Link pending
g889203g0501074536045.jpg Edgar Link pending
g889203g0501074536767.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
bntc-20240930_def.xml Edgar Link unprocessable
bntc-20240930_lab.xml Edgar Link unprocessable
bntc-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d889203d10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bntc-20240930_cal.xml Edgar Link unprocessable